<?xml version='1.0' encoding='utf-8'?>
<document id="21825263"><sentence text="Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein."><entity charOffset="17-29" id="DDI-PubMed.21825263.s1.e0" text="lenalidomide" /><entity charOffset="34-41" id="DDI-PubMed.21825263.s1.e1" text="CCI-779" /><entity charOffset="99-119" id="DDI-PubMed.21825263.s1.e2" text="lenalidomide-CCI-779" /><pair ddi="false" e1="DDI-PubMed.21825263.s1.e0" e2="DDI-PubMed.21825263.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21825263.s1.e0" e2="DDI-PubMed.21825263.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21825263.s1.e0" e2="DDI-PubMed.21825263.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21825263.s1.e1" e2="DDI-PubMed.21825263.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21825263.s1.e1" e2="DDI-PubMed.21825263.s1.e2" /></sentence><sentence text="Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone"><entity charOffset="127-140" id="DDI-PubMed.21825263.s2.e0" text="dexamethasone" /></sentence><sentence text=" The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM"><entity charOffset="32-44" id="DDI-PubMed.21825263.s3.e0" text="lenalidomide" /></sentence><sentence text="" /><sentence text="A phase I clinical trial was initiated for patients with relapsed myeloma with administration of oral lenalidomide on days 1 to 21 and CCI-779 intravenously once per week during a 28-day cycle"><entity charOffset="102-114" id="DDI-PubMed.21825263.s5.e0" text="lenalidomide" /></sentence><sentence text=" Pharmacokinetic data for both agents were obtained, and in vitro transport and uptake studies were conducted to evaluate potential drug-drug interactions" /><sentence text="" /><sentence text="Twenty-one patients were treated with 15 to 25 mg lenalidomide and 15 to 20 mg CCI-779"><entity charOffset="50-62" id="DDI-PubMed.21825263.s8.e0" text="lenalidomide" /></sentence><sentence text=" The maximum-tolerated dose (MTD) was determined to be 25 mg lenalidomide with 15 mg CCI-779"><entity charOffset="61-73" id="DDI-PubMed.21825263.s9.e0" text="lenalidomide" /></sentence><sentence text=" Pharmacokinetic analysis indicated increased doses of CCI-779 resulted in statistically significant changes in clearance, maximum concentrations, and areas under the concentration-time curves, with constant doses of lenalidomide"><entity charOffset="217-229" id="DDI-PubMed.21825263.s10.e0" text="lenalidomide" /></sentence><sentence text=" Similar and significant changes for CCI-779 pharmacokinetics were also observed with increased lenalidomide doses"><entity charOffset="96-108" id="DDI-PubMed.21825263.s11.e0" text="lenalidomide" /></sentence><sentence text=" Detailed mechanistic interrogation of this pharmacokinetic interaction demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate"><entity charOffset="90-102" id="DDI-PubMed.21825263.s12.e0" text="lenalidomide" /></sentence><sentence text="" /><sentence text="The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting"><entity charOffset="46-58" id="DDI-PubMed.21825263.s14.e0" text="lenalidomide" /></sentence><sentence text=" Pharmacokinetic and clinical interactions between lenalidomide and CCI-779 seemed to occur, with in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate"><entity charOffset="51-63" id="DDI-PubMed.21825263.s15.e0" text="lenalidomide" /><entity charOffset="123-135" id="DDI-PubMed.21825263.s15.e1" text="lenalidomide" /><pair ddi="false" e1="DDI-PubMed.21825263.s15.e0" e2="DDI-PubMed.21825263.s15.e0" /><pair ddi="false" e1="DDI-PubMed.21825263.s15.e0" e2="DDI-PubMed.21825263.s15.e1" /></sentence><sentence text=" To our knowledge, this is the first report of a clinically significant P-gp-based drug-drug interaction with lenalidomide"><entity charOffset="110-122" id="DDI-PubMed.21825263.s16.e0" text="lenalidomide" /></sentence><sentence text="" /></document>